Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03), Yahoo Finance reports. During the same quarter in the prior year, the company posted ($0.43) earnings per share.
Achieve Life Sciences Stock Up 1.6 %
NASDAQ:ACHV traded up $0.07 during mid-day trading on Thursday, hitting $4.45. 74,017 shares of the company traded hands, compared to its average volume of 154,808. The stock’s fifty day moving average price is $4.78 and its 200-day moving average price is $4.68. Achieve Life Sciences has a one year low of $3.03 and a one year high of $5.98. The firm has a market cap of $152.82 million, a price-to-earnings ratio of -3.42 and a beta of 1.54.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on ACHV shares. Jonestrading began coverage on Achieve Life Sciences in a research report on Wednesday, April 17th. They issued a “buy” rating and a $20.00 price target on the stock. Oppenheimer reissued an “outperform” rating and issued a $11.00 target price on shares of Achieve Life Sciences in a report on Thursday.
About Achieve Life Sciences
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Read More
- Five stocks we like better than Achieve Life Sciences
- ETF Screener: Uses and Step-by-Step Guide
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Jeff Brown’s Exegesis AI Stock Picks
- What Is WallStreetBets and What Stocks Are They Targeting?
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.